Specifications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Biological activity

Blocks the binding of mouse and Human BAFF to their BAFF-receptors, inhibiting BAFF-mediated splenocyte survival.

Applications

Functional Studies

SDS-PAGE

Flow Cytometry

Endotoxin level

< 0.100 Eu/µg

Purity

>95% by SDS-PAGE .

Form

Lyophilised

Additional notes

Binds Mouse and Human BAFF.
Blocks the binding of mouse and Human BAFF to their BAFF-receptors, inhibiting BAFF-mediated splenocyte survival.

Concentration information loading...

Preparation and Storage

Stability and Storage

Shipped at 4°C. Store at -20°C.

Constituent: 99% PBS

This product is an active protein and may elicit a biological response in vivo, handle with caution.

Reconstitution

Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.

General Info

Alternative names

B cell activating factor receptor

B-cell-activating factor receptor

BAFF R

BAFF receptor

BAFF-R

BAFFR

BLyS receptor 3

BlySR3

BR 3

BR3

BROMIX

CD 268

CD268

CD268 antigen

CVID4

MGC138235

OTTHUMP00000028746

Prolixin

TNFRSF 13C

Tnfrsf13c

TR13C_HUMAN

Tumor necrosis factor receptor subunit member 13C

Tumor necrosis factor receptor superfamily member 13C

see all

Function

B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.

Defects in TNFRSF13C are the cause of immunodeficiency common variable type 4 (CVID4) [MIM:613494]; also called antibody deficiency due to BAFFR defect. CVID4 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.

Images

Inhibition of BAFF-mediated splenocyte survival.
ab157042 inhibits BAFF-mediated activation of freshly isolated splenocytes. Concentration of ab157042 to achieve complete inhibition depends on the concentration of soluble BAFF used. A ratio (soluble BAFF:ab157042) 1:50 and higher is recommended.
Method: On day 0 splenocytes were isolated from a freshly collected C57Bl6 spleen. An aliquot of the splenocytes was analyzed on FACS, and B cells were gated on the SSC-FSC panel. FACS settings were saved. The rest of the cells was put in culture with media alone, with the indicated concentration of recombinant Human soluble BAFF alone or in the presence of an excess of ab157042 (50µg/ml). After three days in culture, cells were again analyzed on FACS with the saved setting. Splenocytes survival index (=ratio of %living/%dead cells) was calculated and plotted.

References

ab157042
has not yet been referenced specifically in any publications.

Publishing research using ab157042? Please let us know so that we can cite the reference in this datasheet.